ClinicalTrials.gg
WithdrawnNCT03902067Updated May 11, 2026

UC-MSC Transplantation for Left Ventricular Dysfunction After AMI

A Phase 1 interventional study of UC-MSC and Control Group in Left Ventricular Dysfunction and Acute Myocardial Infarction, sponsored by Shanghai Life Science & Technology. Withdrawn at 1 site in China. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Shanghai Life Science & Technology · Phase 1, Interventional, and Treatment

Why this study was withdrawn
budget control

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Ventricular Dysfunction, Left with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Ventricular Dysfunction, Left · China.

Started
2024
the only one that year
Phase 1
Only one
of the 15
Registered
4th of 15
by date

Among the 15 studies in Ventricular Dysfunction, Left with a site in China, this one is the only one that started in 2024, is the only one in phase 1, and was the 4th registered.

Ventricular Dysfunction, Left

260 studies on the registry are indexed under Ventricular Dysfunction, Left; 57 are open to participants now.

Browse Ventricular Dysfunction, Left studies →

Open to participants now

6 of the 15 studies in Ventricular Dysfunction, Left with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 38 Ventricular Dysfunction, Left studies recruiting now, 21 (55%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Ventricular Dysfunction, Left with a site in China, or all of them as a file.
02

Study summary

A pilot study to evaluate the safety and feasibility of umbilical cord mesenchymal stem cells in the treatment of acute myocardial infarction by catheter transplantation

Read the detailed description

In this study, 40 patients with cardiac insufficiency after acute myocardial infarction were selected and randomly divided into umbilical cord MSCs transplantation treatment group and non-intervention control group to preliminarily observe the safety and effectiveness of MSCs cell transplantation treatment.

03

Conditions studied

  • Left Ventricular Dysfunction
  • Acute Myocardial Infarction

Keywords

  • AMI
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with acute extensive anterior myocardial infarction were successfully treated with emergency interventional therapy within 12 hours after onset. was less than 0.35 by echocardiography 30 days after operation, scar area was more than 25% by MRI, and cardiac function was III-IV grade.
  • Fully inform the purpose, method and possible side effects of the test, agree to the test, and sign an form;
  • Good compliance, willing to take drugs and follow up according to the requirements of the plan;
  • exceeds one year.

Exclusion criteria

Exclusion Criteria:

  • Those who cannot tolerate cell therapy;
  • Patients with severe hepatic and renal insufficiency (>1.5 times the value, Cr >1.5 times the upper limit of normal value);
  • Patients with malignant tumors or extremely weak patients;
  • Patients with severe infection;
  • Patients who are expected to have the second coronary intervention or bypass grafting within 3 months;
  • Patients with other serious systemic diseases and organ dysfunction;
  • Patients with cardiogenic shock;
  • Patients with hemorrhagic diseases;
  • Researchers believe that anyone who is not suitable for inclusion
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    UC-MSC

    UC-MSC transplantation

    Biological: UC-MSC

  • Placebo comparator
    Control Group

    Routine treatment

    Biological: Control Group

Interventions

  • BiologicalUC-MSC

    0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5x10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability\>80%, and endotoxin\<0.1 EU, at the concentration of 2x10(7) cells/ml.

    Also known as: Transplantation Group

  • BiologicalControl Group

    Routine treatment without catheter infusion

06

What researchers measure

Primary outcomes

  1. Safety measured as the number of Major Adverse Cardiac Events (MACE)

    Possible adverse events, including adverse events that may occur during angiography and infusion of transplanted cells such as chest pain, arrhythmia, slow blood flow, myocardial injury, fever, allergic reaction, postoperative infection, etc.

    Time frame: 12 months

Secondary outcomes

  1. Difference in left ventricular ejection fraction measured by magnetic resonance imaging at baseline and 12 months follow-up

    left ventricular ejection fraction measured by magnetic resonance imaging

    Time frame: 12 months

07

Study locations

1 site
  • Shanghai Jiao Tong University Affiliated Sixth People's Hospital
    Shanghai, Shanghai Municipality 200233, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2024; primary completion for Dec 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2019
First posted
Apr 3, 2019
StartEst.
Dec 1, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03902067
Lead sponsor
Shanghai Life Science & Technology
Collaborators
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Responsible party
Sponsor
First posted
Apr 3, 2019
Start date
Dec 1, 2024 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
May 11, 2026

Study contacts

Chengxing Shen, Dr.
principal investigator · Shanghai Jiao Tong University Affiliated Sixth People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion